{"id":"NCT00375492","sponsor":"AstraZeneca","briefTitle":"Effect on Weight Loss of Exenatide Versus Placebo","officialTitle":"Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2006-09-13","resultsPosted":"2009-09-04","lastUpdate":"2015-04-07"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfonylurea. Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program.","primaryOutcome":{"measure":"Change From Baseline in Body Weight","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Group A (Exenatide)","deltaMin":-6.16,"sd":0.54},{"arm":"Group B (Placebo)","deltaMin":-3.97,"sd":0.52}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0030"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["22913891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Nausea","Diarrhea","Upper respiratory tract infection","Vomiting","Headache"]}}